Genesis Healthcare: Sale Rejected as Judge Finds "Too Many Irregularities"

Genesis Healthcare, Inc., once the largest skilled nursing facility operator in the United States, filed for chapter 11 bankruptcy on July 9, 2025. The Kennett Square, Pennsylvania-based company—which operates approximately 175 skilled nursing facilities and senior living centers across 18 states, employing 27,000 workers and serving more than 15,000 residents—entered bankruptcy carrying $708 million in secured debt, over $1.5 billion in unsecured debt, and at least $259 million owed to plaintiffs in more than 200 pending malpractice and wrongful death lawsuits.

The case shifted in December 2025 when U.S. Bankruptcy Judge Stacey G.C. Jernigan rejected the proposed sale to insiders and ordered a fresh auction under U.S. Trustee oversight. The judge found "too many irregularities" in the auction process and refused to approve the sale with legal releases from liability for Joel Landau, the ReGen Healthcare founder whose affiliated entities acquired 93% of Genesis equity in 2023 before serving as stalking horse bidder. The U.S. Trustee's Office and the Official Committee of Unsecured Creditors had both objected to the sale terms.

The case has drawn congressional scrutiny from Senators Elizabeth Warren, Richard Blumenthal, and Peter Welch, along with Representative Maggie Goodlander, who filed a brief supporting creditor objections and demanded investigation into whether Genesis is "exploiting the bankruptcy system" to avoid paying victims and families. With facility quality ratings declining from 38% above-average to 15% under ReGen's ownership, and allegations that Genesis delayed paying $41 million of $58 million promised to plaintiff families in the years before filing, the case includes issues tied to private equity ownership and patient care quality.

Once the Largest SNF Operator in America

Genesis Healthcare's origins trace to 1985, when founders Michael Walker and Richard Howard acquired nine skilled nursing facilities with a vision of transforming nursing homes into proactive healthcare centers rather than custodial facilities for the elderly. The company grew rapidly through acquisitions, reaching $2.4 billion in revenue by 1998 before the Balanced Budget Act of 1997 forced Medicare cuts that pushed the company into chapter 11 protection in 2000. Genesis emerged in 2001 as a reorganized company and spun off its pharmacy division in 2003, adopting the NeighborCare name while the skilled nursing operations became Genesis HealthCare Corporation.

The Formation Capital era (2007-2023). In July 2007, Genesis HealthCare Corporation merged with FC-GEN Acquisition, Inc. in a leveraged buyout valued at approximately $1.52 billion, led by affiliates of Formation Capital, LLC and JER Partners. At the time, the portfolio consisted of 180 owned and leased facilities comprising more than 21,800 beds.

On April 1, 2011, Genesis transferred substantially all of its real property interests to Health Care REIT, Inc. (now Welltower, Inc.) in exchange for $2.4 billion, converting from an owner-operator model to a pure lessee dependent on master lease agreements with its former real estate. The transaction included 147 post-acute, skilled nursing, and assisted living facilities in 11 states. A report from the Private Equity Stakeholder Project alleges that Formation Capital utilized "leveraged buyouts, sale-leaseback transactions and layered debt to extract value" from Genesis, characterizing the strategy as "asset stripping, high-risk borrowing, and recurring regulatory violations."

The expansion continued. In December 2012, Genesis acquired Sun Healthcare Group, Inc., creating one of the largest skilled nursing providers with more than 400 facilities in 29 states. In February 2015, Genesis merged with Skilled Healthcare Group, Inc., expanding to more than 500 facilities in 34 states—making it the largest skilled nursing operator in the United States. At its peak in 2016, Genesis operated over 500 facilities with more than 60,000 licensed beds across 30+ states.

The ReGen Healthcare era (2023-present). The COVID-19 pandemic weakened Genesis's finances, and by late 2020, the company was preparing for chapter 11. A capital infusion from ReGen Healthcare, a private investment entity, and a master lease restructuring with Welltower allowed the company to avoid bankruptcy in March 2021.

Joel Landau, founder and owner of ReGen Healthcare, which is affiliated with Pinta Capital Partners, emerged as the controlling force behind Genesis. If fully converted to equity, the ReGen Notes would provide ReGen rights to approximately 93% of the voting shares. ReGen appointed three members to the Genesis board, including the chairman.

Contemporaneously with the initial ReGen investment in March 2021, the company agreed to terminate its master lease covering 51 facilities leased from Welltower affiliates and transition those operations to new operators. Genesis also voluntarily delisted from the NYSE, with its stock now trading over-the-counter on the pink-sheet market. The combined effect was to take the company private under ReGen's control while shedding a significant portion of its portfolio—though liabilities from the shed facilities remained.

Geographic footprint. At the time of filing, Genesis operates approximately 175 facilities across 18 states. New Hampshire alone has 16 Genesis nursing homes, with concerns about "instability" at those facilities prompting state-level scrutiny. The company maintains significant operations in Pennsylvania (where it is headquartered), New Jersey, and Delaware. The ancillary businesses—including Genesis Rehabilitation Services, respiratory therapy, and a captive accountable care organization—extend the company's footprint to approximately 40 states.

Quality ratings under ReGen. According to congressional investigators, the proportion of Genesis facilities rated above average (4-5 stars) by the Centers for Medicare & Medicaid Services declined from 38% to 15% between ReGen's 2023 acquisition and the bankruptcy filing—a decline of more than 60% in above-average facilities during a two-year period.

Reasons for Filing

Genesis's First Day Declaration, submitted by Co-Chief Restructuring Officer Louis E. Robichaux IV of Ankura Consulting Group, identifies multiple interrelated factors that pushed the company into chapter 11.

Pandemic aftereffects. The declaration states that "the after-effects of the pandemic on the skilled nursing industry generally, and Genesis HealthCare specifically, cannot be overstated." COVID-19 led to higher operating costs for labor, supplies, and personal protective equipment. The company became heavily reliant on expensive staffing agencies, which substantially increased labor costs—already the company's largest expense. Elective procedures at neighboring hospitals were postponed, reducing referrals. Certain facilities required dedicated "COVID wings," and family visitation restrictions limited the ability of residents to connect with loved ones.

Inadequate Medicaid reimbursement. Genesis executives cited low state Medicaid reimbursement rates as a primary cause of distress. Pennsylvania, where Genesis is headquartered, is the company's fourth-largest unsecured creditor with approximately $58 million in unpaid tax claims. Insufficient reimbursement rates in Pennsylvania and New Jersey were identified as notable contributors to the company's financial challenges.

Legacy liabilities from expansion. As Genesis rationalized its lease portfolio from over 500 facilities to the approximately 175 it operates today, it remained responsible for liabilities associated with a much larger footprint. The First Day Declaration describes the company as having corporate guarantees, cross-collateralization, and legacy liabilities dating back decades.

Litigation costs. Prior to the bankruptcy filing, Genesis was spending approximately $8 million per month defending and settling malpractice and wrongful death lawsuits—funds the company asserted could otherwise be used for direct resident care or capital expenditures. Many claims predate the pandemic and relate to facilities no longer operated by the company.

Delayed Settlement Payments to Victims

The bankruptcy has intensified scrutiny of Genesis's treatment of malpractice and wrongful death claimants. A CBS News investigation revealed that in the years before bankruptcy, Genesis settled at least 155 patient injury and death lawsuits with delayed payment provisions, some allowing delays of more than a year before payment was due.

At the time of filing, Genesis still owed $41 million of the $58 million it had promised to plaintiff families in settlement agreements. Critics argue that the settlement timing reduced near-term payments to claimants before the filing.

Skilled Nursing News reported that some experts estimate Genesis's total debts to victims could reach $344 million, accounting for both settled and unsettled claims.

Congressional response. The delayed payment allegations prompted Senators Elizabeth Warren, Richard Blumenthal, and Peter Welch, along with Representative Maggie Goodlander, to demand an investigation by the U.S. Trustee. In a November 12, 2025 letter to the Acting Director of the Executive Office for U.S. Trustees, the lawmakers expressed concern about whether Genesis is "exploiting the bankruptcy system" to avoid paying victims and families.

The congressional investigation also examined the role of private equity in Genesis's decline. In an October 2025 inquiry, the lawmakers noted that ReGen's $100 million investment—which provided 93% equity ownership and three board seats—coincided with the decline in facility quality ratings.

Rejected Sale and Auction Irregularities

Genesis entered bankruptcy with a stalking horse bid from ReGen Healthcare and Pinta Capital Partners—the same affiliated entities that already controlled the company. The proposed transaction contemplated the purchase of substantially all of Genesis's assets, with a condition: legal releases from liability for Joel Landau.

Initial sale timeline. The company filed its Bidding Procedures Motion on July 15, 2025, and the court entered the Bidding Procedures Order on August 28, 2025. The sale hearing was scheduled for December 10-11, 2025.

Objections mounted. As the sale hearing approached, objections increased. The Official Committee of Unsecured Creditors filed objections to both the bidding procedures and the proposed sale. The U.S. Trustee's Office raised concerns about the auction process. Senators Warren, Blumenthal, Welch, and Representative Goodlander filed a brief in support of creditor objections, adding congressional weight to the opposition.

December 2025: Sale rejected. Following the two-day sale hearing, Judge Jernigan rejected the sale outright. The judge found "too many irregularities" in the auction process and refused to approve the sale with the legal releases that Landau had sought as a condition of the transaction.

The ruling rejected the insider sale and denied requested releases.

New auction ordered. Judge Jernigan directed that a new auction be conducted in January 2026 under the oversight of the U.S. Trustee's Office. The fresh marketing process provides what KFF Health News described as "fresh hope of compensation" for victim families who had faced the prospect of receiving pennies on the dollar—or nothing at all—under the original sale terms.

Contested Matters and Stakeholder Dynamics

The Genesis bankruptcy has featured litigation among stakeholders, with personal injury claimants, the unsecured creditors committee, and the U.S. Trustee challenging aspects of the debtors' conduct and proposed transactions.

Personal injury claimants seek relief from stay. Approximately 200 plaintiffs with pending malpractice and wrongful death claims have sought relief from the automatic stay to pursue their litigation. Multiple motions were filed within weeks of the petition date. The claims span states where Genesis operates or previously operated, including New Mexico, Kentucky, and West Virginia, which the First Day Declaration identifies as states with "limited or no tort reform" where litigation exposure has been particularly acute.

Discovery disputes. The case has featured disputes over discovery between the debtors and the unsecured creditors committee, including motions for sanctions and to compel discovery filed in December 2025. The timing was just before the sale hearing.

Stay extension contested. The debtors moved to extend the automatic stay in September 2025, with the motion receiving 39 references from other docket filings—indicating significant stakeholder interest in the outcome. Personal injury claimants opposed the extension, arguing that they should be permitted to pursue their claims against insurance proceeds or other sources.

Exclusivity objections. Creditors objected to the debtors' request to extend the exclusivity period for filing a plan.

Special Investigation Committee. The First Day Declaration reveals that prior to filing, Genesis formed a Special Investigation Committee of independent directors, advised by independent special counsel from Katten Muchin Rosenman LLP. The committee conducted a "comprehensive pre-petition investigation" into potential claims and causes of action proposed to be purchased or released under the stalking horse bid.

DIP Financing

Genesis secured $30 million in debtor-in-possession financing from its existing secured lenders to fund operations through the sale process. The DIP Motion was approved on an interim basis on July 11, 2025, with the Final DIP Order entered on August 28, 2025. The DIP facility was funded on a junior basis by the company's prepetition term loan lenders.

The $30 million DIP is small relative to Genesis's approximately $2.2 billion total debt load and operations.

Professional Retentions and Patient Care Oversight

The complexity and scale of the Genesis bankruptcy required engagement of numerous restructuring professionals.

Patient care ombudsman. Given the healthcare nature of the debtors, Susan N. Goodman was appointed as Health Care Ombudsman to monitor patient care quality at Genesis's approximately 175 facilities during the bankruptcy. The ombudsman has filed multiple reports, including a third report in December 2025 covering the monitoring period from October 15 through December 13, 2025. The appointment reflects the court's recognition that bankruptcy proceedings in healthcare cases must balance creditor interests with the welfare of vulnerable patient populations.

Prepetition Capital Structure

Genesis entered bankruptcy with a capital structure reflecting years of leveraged transactions, sale-leasebacks, and rescue financing.

The lien priorities among the various secured lenders are governed by a web of intercreditor and subordination agreements. White Oak Healthcare Finance, LLC holds first-priority liens on receivables through its asset-based lending facilities, while the term loan lenders—including affiliates of Welltower, Omega Healthcare Investors, and other healthcare REITs—hold security interests in the company's remaining assets, including equity interests in joint ventures.

Secured Debt.

The secured debt structure includes asset-based lending facilities from White Oak Healthcare Finance, LLC, and term loans from a consortium of healthcare REITs including affiliates of Welltower, Omega Healthcare Investors, and other institutional lenders.

Unsecured Debt.

The unsecured debt reflects the company's financial obligations and litigation exposure. Pennsylvania's $58 million tax claim makes the Commonwealth one of the largest unsecured creditors.

The MAO and WAX unsecured notes originated from December 2016 loan agreements that were initially secured by real estate assets no longer owned by the company. In September 2024, Welltower assigned approximately $320 million of these obligations to MAO and the remaining $26.5 million to WAX. These loans accrue interest at 12.0% per annum, with all interest paid-in-kind—further inflating the unsecured debt burden.

The ReGen Notes, while subordinated and convertible, represent the investment that gave ReGen control over the company. If converted, these notes would provide ReGen with approximately 93% of Genesis's voting shares on a fully diluted basis. The first note, issued in March 2021, matures in March 2026 and bears interest at just 1.0% per annum, while later notes carry progressively higher interest rates—with the fourth note issued in May 2023 bearing interest at 1.5% per month, paid-in-kind.

Skilled Nursing Industry Conditions

Genesis's bankruptcy follows increased filings in the skilled nursing industry. Senior Housing News reported that senior care bankruptcy filings hit a two-year high in Q1 2025, increasing from three in Q4 2024 to seven—accounting for more than 40% of total healthcare bankruptcy filings.

Bloomberg Law analysis notes that since 2020, 774 nursing homes have closed, resulting in the loss of 62,567 beds and displacement of 28,421 residents.

Factors driving distress. Industry representatives attribute the wave of bankruptcies to multiple factors: inadequate Medicaid reimbursement rates that fail to cover the cost of care, persistent post-pandemic workforce shortages that have driven up labor costs, an increasingly burdensome regulatory environment, and a legal environment with significant litigation exposure.

Looming funding cuts. ACPlus industry analysis warns that the "One Big Beautiful Bill Act" will trim nearly $1 trillion from Medicaid, with nursing homes potentially facing $500 billion in Medicare sequestration cuts from 2026 to 2034.

Judge Jernigan's rejection of the insider sale and her direction to conduct a new auction under U.S. Trustee oversight are central developments in the case.

Key Timeline

Frequently Asked Questions

What is Genesis Healthcare and why did it file bankruptcy?

Genesis Healthcare, Inc. was once the largest skilled nursing facility operator in the United States, operating approximately 175 facilities across 18 states with 27,000 employees and 15,000+ residents at the time of filing. It filed for chapter 11 on July 9, 2025, burdened with over $708 million in secured debt, approximately $1.57 billion in unsecured debt, and 200+ pending malpractice and wrongful death lawsuits representing at least $259 million in estimated liability. The company cited pandemic aftereffects, inadequate Medicaid reimbursement, legacy liabilities from prior expansion, and substantial litigation defense costs of approximately $8 million monthly.

Why did the judge reject the sale?

U.S. Bankruptcy Judge Stacey G.C. Jernigan rejected the sale to ReGen Healthcare/Pinta Capital Partners in December 2025, finding "too many irregularities" in the auction process. She refused to approve the sale with legal releases from liability for Joel Landau, the ReGen founder who controlled 93% of Genesis equity. Both the U.S. Trustee's Office and the Official Committee of Unsecured Creditors had objected to the transaction.

What role did private equity play in the bankruptcy?

Genesis underwent two major private equity periods. Formation Capital and JER Partners acquired the company in a 2007 leveraged buyout worth approximately $1.5 billion, then executed a 2011 sale-leaseback of 147 properties to Welltower for $2.4 billion—converting Genesis from an owner to a lessee. In 2023, ReGen Healthcare acquired approximately 93% equity for $100 million in rescue financing. Reports allege these transactions involved "asset stripping, high-risk borrowing, and recurring regulatory violations."

What happened to facility quality under ReGen's ownership?

According to congressional investigators, the proportion of Genesis facilities rated above average (4-5 stars) by CMS declined from 38% to 15% between ReGen's 2023 acquisition and the bankruptcy filing—a decline of more than 60% in above-average facilities during a two-year period.

What are the allegations about delayed payments to victims?

In the years before bankruptcy, Genesis settled at least 155 patient injury and death lawsuits with delayed payment provisions, some allowing delays of more than a year. At filing, Genesis still owed $41 million of the $58 million promised to plaintiff families in settlement agreements. Critics allege Genesis delayed payments before the filing.

What is the congressional investigation about?

Senators Elizabeth Warren, Richard Blumenthal, Peter Welch, and Representative Maggie Goodlander are investigating whether Genesis is "exploiting the bankruptcy system" to avoid paying victims. They filed a brief supporting creditor objections and sent a letter to the U.S. Trustee requesting investigation into the company's conduct, the role of private equity ownership, and the impact on 15,000+ residents and 27,000 employees.

What happens next?

Judge Jernigan ordered a new auction to be conducted in January 2026 under oversight of the U.S. Trustee's Office.

Who is Joel Landau and why are the releases significant?

Joel Landau is the founder and owner of ReGen Healthcare, affiliated with Pinta Capital Partners. ReGen acquired 93% of Genesis equity for approximately $100 million and placed three directors on the board. Landau sought legal releases from liability as a condition of the stalking horse purchase, which the court refused to grant. The releases would have protected Landau from claims related to Genesis's decline under his control.

Is patient care being monitored during the bankruptcy?

Yes. Susan N. Goodman was appointed as Health Care Ombudsman to monitor patient care quality at Genesis's approximately 175 facilities. She has filed multiple reports during the bankruptcy, including a third report in December 2025. The ombudsman role provides the court with independent assessments of patient care during the restructuring process.

What is the broader skilled nursing industry outlook?

The skilled nursing industry has seen rising bankruptcies. Senior care bankruptcies hit a two-year high in Q1 2025, and since 2020, 774 nursing homes have closed, displacing over 28,000 residents. Looming Medicaid cuts (nearly $1 trillion) and Medicare sequestration ($500 billion from 2026-2034) add pressure.

Who is the claims agent for Genesis Healthcare?

Epiq Corporate Restructuring, LLC serves as the claims and noticing agent. The firm maintains the official claims register and distributes case notifications to creditors and parties in interest.

---

For more bankruptcy case analyses and restructuring insights, visit ElevenFlo's bankruptcy blog.